Ambiguous claims can invalidate patents

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Ambiguous claims can invalidate patents

pills.jpg

The result

Supreme Court of Canada invalidated Pfizer’s patent on the active ingredient in Viagra

The impact

The sufficient disclosure test must be applied to the patent as a whole

In Teva v Pfizer, generic manufacturer Teva Canada sued Pfizer, alleging that its patent on sildenafil, the active ingredient in Viagra, was invalid.

The patent covers seven claims, with claim 1 describing a formula which covers 260 quintillion compounds. Claims two to five successively narrow down the ranges of compounds. Claims 6 and 7 each cover a single compound, with claim 7 describing sildenafil. The patent lists nine "especially preferred" compounds, including sildenafil. However, it fails to specify that sildenafil is the only compound that Pfizer found induced erections.

Teva argued that the patent, number 2,163,446, failed to properly disclose the invention, as required under Section 27(3) of the Patent Act. Pfizer disagreed, also arguing that under Section 58 of the Act, courts are required to consider valid and invalid claims separately. Despite describing claims 1 to 5 as "red herrings", The Federal Court of Appeal upheld the patent on this basis.

But the Supreme Court of Canada overruled the decision, concluding that the test was whether a skilled person could reproduce the invention using only the information in the patent. Pfizer's patent would require experimentation to discover whether claim 6 or 7 contained the effective compound.

The court invalidated the patent 18 months before its expiration date. The day the Supreme Court released its ruling, Teva launched Novo-Sildenafil, a generic version of Viagra.

This case was selected as one of Managing IP’s Cases of the Year for 2012.

To see the rest, click on one of the cases below.

The 10 cases of the year

A fillip for the EU pharmaceutical sector

Relief for trade mark owners in red sole saga

Australian TV streaming service held to be illegal

Smartphone war hits front page in the US

Liberalising the EU’s software market

India allows parallel imports

Victory for fair dealing in Canada

Lacoste loses its trade mark in China

Google prevails in Android attack

EU test case clarifies class headings

Ten you might have missed

Canada: Ambiguous claims can invalidate patents

Russia: Certainty on parallel imports

Italy: TV formats win copyright for the first time

First FRAND cases litigated worldwide

Monsanto loses in Brazil

Data exclusivity backed by Mexican courts

China: A shift over OEM manufacturing

Authors in the US able to reclaim joint copyrights

Germany: Knitted trainers a sign of the future

India: Financial Times loses trade mark

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article